SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market.

CapsoVision (NASDAQ: CV - Get Free Report) and Biosig Technologies (NASDAQ: STEX - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability. Profitability This table compares CapsoVision and Biosig Technologies'

CapsoVision, Inc. (NASDAQ: CV - Get Free Report) saw a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 429,030 shares, an increase of 19.9% from the January 29th total of 357,735 shares. Based on an average daily volume of 213,138 shares, the days-to-cover ratio is

CapsoVision (NASDAQ: CV - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Insider and Institutional Ownership 9.8% of Profusa shares are

CNBC's Brian Sullivan reports on President Trump's commentary about Venezuela's oil industry during his meeting with oil executives at the White House.

Shares of CapsoVision, Inc. (NASDAQ: CV - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $12.39, but opened at $10.85. CapsoVision shares last traded at $11.05, with a volume of 7,782 shares trading hands. Analysts Set New Price Targets Several equities research analysts have recently weighed in

CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.

CapsoVision, Inc. (NASDAQ: CV - Get Free Report)'s share price traded down 6.5% on Friday. The stock traded as low as $12.90 and last traded at $12.98. 11,088 shares were traded during trading, a decline of 93% from the average session volume of 163,197 shares. The stock had previously closed at $13.88. Wall Street Analysts

CapsoVision's (NASDAQ: CV - Get Free Report) lock-up period will expire on Monday, December 29th. CapsoVision had issued 5,500,000 shares in its initial public offering on July 2nd. The total size of the offering was $27,500,000 based on an initial share price of $5.00. After the expiration of CapsoVision's lock-up period, company insiders and major shareholders